The rising use of GLP-1 medications, such as Novo Nordisk’s Wegovy and Ozempic, for weight loss has driven up patients’ visits to their physicians, resulting in more frequent diagnoses of other health issues, Finimize reported Dec. 16.
GLP-1s driving up healthcare usage: 5 things to know
